Literature DB >> 25136012

Validation of a model to predict the risk of nephrotoxicity in patients receiving colistin.

Kady Phe1, Michael L Johnson2, Hannah R Palmer3, Vincent H Tam4.   

Abstract

Despite concerns about its nephrotoxicity, colistin often remains the only effective agent for treating multidrug-resistant Gram-negative infections. Published studies have reported a wide range of nephrotoxicity risk factors. To assess the clinical utility of various models, we compared their performances for predicting the risk of nephrotoxicity. We identified a model demonstrating reasonable overall risk assessment, with an observed/expected ratio of 1.29 (95% confidence interval [CI], 0.68 to 1.90) and a positive predictive value of 87.5% for identifying patients at high risk of developing nephrotoxicity.
Copyright © 2014, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25136012      PMCID： PMC4249357          DOI： 10.1128/AAC.03776-14

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  16 in total

1.  Colistin treatment in patients with ICU-acquired infections caused by multiresistant Gram-negative bacteria: the renaissance of an old antibiotic.

Authors:  A S Michalopoulos; S Tsiodras; K Rellos; S Mentzelopoulos; M E Falagas
Journal:  Clin Microbiol Infect       Date:  2005-02       Impact factor: 8.067

2.  Colistin therapy for microbiologically documented multidrug-resistant Gram-negative bacterial infections: a retrospective cohort study of 258 patients.

Authors:  Matthew E Falagas; Petros I Rafailidis; Elda Ioannidou; Vangelis G Alexiou; Dimitrios K Matthaiou; Drosos E Karageorgopoulos; Anastasios Kapaskelis; Dimitra Nikita; Argyris Michalopoulos
Journal:  Int J Antimicrob Agents       Date:  2009-12-16       Impact factor: 5.283

3.  In vitro assessment and multicenter cohort study of comparative nephrotoxicity rates associated with colistimethate versus polymyxin B therapy.

Authors:  Kady Phe; Yuman Lee; Patrick M McDaneld; Nishant Prasad; Taijun Yin; Deborah A Figueroa; William L Musick; Jessica M Cottreau; Ming Hu; Vincent H Tam
Journal:  Antimicrob Agents Chemother       Date:  2014-02-24       Impact factor: 5.191

4.  Nephrotoxicity associated with intravenous colistin in critically ill patients.

Authors:  Neha M Doshi; Kari L Mount; Claire V Murphy
Journal:  Pharmacotherapy       Date:  2011-12       Impact factor: 4.705

5.  Impact of multidrug-resistant Pseudomonas aeruginosa bacteremia on patient outcomes.

Authors:  Vincent H Tam; Cary A Rogers; Kai-Tai Chang; Jaye S Weston; Juan-Pablo Caeiro; Kevin W Garey
Journal:  Antimicrob Agents Chemother       Date:  2010-06-28       Impact factor: 5.191

6.  Incidence of and risk factors for colistin-associated nephrotoxicity in a large academic health system.

Authors:  Jason M Pogue; Jiha Lee; Dror Marchaim; Victoria Yee; Jing J Zhao; Teena Chopra; Paul Lephart; Keith S Kaye
Journal:  Clin Infect Dis       Date:  2011-09-07       Impact factor: 9.079

7.  The impact of multidrug resistance on the outcomes of critically ill patients with Gram-negative bacterial pneumonia.

Authors:  Andrea L H Kwa; Jenny G H Low; Erin Lee; Asok Kurup; Huei-Leng Chee; Vincent H Tam
Journal:  Diagn Microbiol Infect Dis       Date:  2007-02-14       Impact factor: 2.803

8.  Predictors of acute kidney injury associated with intravenous colistin treatment.

Authors:  Jeong-Ah Kwon; Jung Eun Lee; Wooseong Huh; Kyong Ran Peck; Yoon-Goo Kim; Dae Joong Kim; Ha Young Oh
Journal:  Int J Antimicrob Agents       Date:  2010-01-20       Impact factor: 5.283

9.  Nephrotoxicity associated with intravenous colistin (colistimethate sodium) treatment at a tertiary care medical center.

Authors:  Joshua D Hartzell; Robert Neff; Julie Ake; Robin Howard; Stephen Olson; Kristopher Paolino; Mark Vishnepolsky; Amy Weintrob; Glenn Wortmann
Journal:  Clin Infect Dis       Date:  2009-06-15       Impact factor: 9.079

10.  Intravenous colistin in the treatment of sepsis from multiresistant Gram-negative bacilli in critically ill patients.

Authors:  Nikolaos Markou; Haralampos Apostolakos; Christiana Koumoudiou; Maria Athanasiou; Alexandra Koutsoukou; Ioannis Alamanos; Leonidas Gregorakos
Journal:  Crit Care       Date:  2003-07-28       Impact factor: 9.097
View more
  8 in total

Review 1.  Clinical Pharmacokinetics and Pharmacodynamics of Colistin.

Authors:  Nicolas Grégoire; Vincent Aranzana-Climent; Sophie Magréault; Sandrine Marchand; William Couet
Journal:  Clin Pharmacokinet       Date:  2017-12       Impact factor: 6.447

Review 2.  Critical evaluation of ceftolozane-tazobactam for complicated urinary tract and intra-abdominal infections.

Authors:  Stephanie E Giancola; Monica V Mahoney; Tiffany E Bias; Elizabeth B Hirsch
Journal:  Ther Clin Risk Manag       Date:  2016-05-19       Impact factor: 2.423

3.  Defining the incidence and risk factors of colistin-induced acute kidney injury by KDIGO criteria.

Authors:  Ryan K Shields; Rohit Anand; Lloyd G Clarke; Julie A Paronish; Matthew Weirich; Hanna Perone; Jake Kieserman; Henry Freedy; Christina Andrzejewski; Hector Bonilla
Journal:  PLoS One       Date:  2017-03-07       Impact factor: 3.240

4.  Hypoalbuminemia as a predictor of acute kidney injury during colistin treatment.

Authors:  Daniele Roberto Giacobbe; Alessandra di Masi; Loris Leboffe; Valerio Del Bono; Marianna Rossi; Dario Cappiello; Erika Coppo; Anna Marchese; Annarita Casulli; Alessio Signori; Andrea Novelli; Katja Perrone; Luigi Principe; Alessandra Bandera; Luca Enrico Vender; Andrea Misin; Pierpaolo Occhilupo; Marcello Melone; Paolo Ascenzi; Andrea Gori; Roberto Luzzati; Claudio Viscoli; Stefano Di Bella
Journal:  Sci Rep       Date:  2018-08-10       Impact factor: 4.379

Review 5.  An Approach to Measuring Colistin Plasma Levels Regarding the Treatment of Multidrug-Resistant Bacterial Infection.

Authors:  Tatiana Pacheco; Rosa-Helena Bustos; Diana González; Vivian Garzón; Julio-Cesar García; Daniela Ramírez
Journal:  Antibiotics (Basel)       Date:  2019-07-24

Review 6.  Antimicrobial therapeutic drug monitoring in critically ill adult patients: a Position Paper.

Authors:  Mohd H Abdul-Aziz; Jan-Willem C Alffenaar; Matteo Bassetti; Hendrik Bracht; George Dimopoulos; Deborah Marriott; Michael N Neely; Jose-Artur Paiva; Federico Pea; Fredrik Sjovall; Jean F Timsit; Andrew A Udy; Sebastian G Wicha; Markus Zeitlinger; Jan J De Waele; Jason A Roberts
Journal:  Intensive Care Med       Date:  2020-05-07       Impact factor: 17.440

Review 7.  Optimizing Antimicrobial Drug Dosing in Critically Ill Patients.

Authors:  Pedro Póvoa; Patrícia Moniz; João Gonçalves Pereira; Luís Coelho
Journal:  Microorganisms       Date:  2021-06-28

8.  Characteristics, Influencing Factors, Predictive Scoring System, and Outcomes of the Patients with Nephrotoxicity Associated with Administration of Intravenous Colistin.

Authors:  Pornpen Sangthawan; Alan Frederick Geater; Surarit Naorungroj; Piyarat Nikomrat; Ozioma Forstinus Nwabor; Sarunyou Chusri
Journal:  Antibiotics (Basel)       Date:  2021-12-21
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.